Back to top

Image: Bigstock

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

Read MoreHide Full Article

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.

FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.

What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?

Catalyst Pharmaceutical's Business In-Depth

With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers. Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults. LEMS is an ultra-rare disease and the company estimates approximately 3,000 LEMS patients in the United States.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.

Catalyst also recently received an FDA approval for its supplemental new drug application (sNDA) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS.
Apart from Firdapse, Catalyst Pharmaceuticals is working on a generic version of Lundbeck’s Sabril (vigabatrin), CPP-109, for the treatment of infantile spasms and complex partial seizures. The company is also looking towards opportunities to diversify its business as well as invest in innovative opportunities for rare diseases.
Catalyst recorded revenues worth $141 million for 2021, reflecting an increase of 18% on a year-over-year basis

Bottom Line

While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Catalyst Pharmaceutical ten years ago, you're probably feeling pretty good about your investment today.

A $1000 investment made in December 2012 would be worth $32,930.69, or a gain of 3,193.07%, as of December 2, 2022, according to our calculations. This return excludes dividends but includes price appreciation.

Compare this to the S&P 500's rally of 187.86% and gold's return of 1.08% over the same time frame.

Going forward, analysts are expecting more upside for CPRX.

Catalyst’s earnings and revenues beat estimates for third-quarter 2022. The company’s lead drug Firdapse, approved for treating Lambert-Eaton Myasthenic Syndrome — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. Zacks analysts are optimistic about this trend and expect the same to continue in 2022. The company’s efforts to develop Firdapse for other rare neuromuscular indications are also impressive. The FDA recently approved the label expansion of Firdapse for treating LEMS in pediatric patients, which is likely to boost Catalyst’s top line. The stock has outperformed the industry year to date. However, overdependence on Firdapse for growth and the lack of any other promising candidates in its pipeline are major concerns. The stiff competition also remains a woe.

The stock is up 18.96% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 4 higher, for fiscal 2022. The consensus estimate has moved up as well.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Catalyst Pharmaceuticals, Inc. (CPRX) - free report >>

Published in